Evidence map›Paper›PMID 35867209›Full record

ArticleAnnals of surgical oncology2022

An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma.

Adrienne B Shannon, Richard J Straker, Michael J Carr, James Sun, Karenia Landa, Kirsten Baecher, Kevin Lynch, Harrison G Bartels, Robyn Panchaud, Luke J Keele and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Adrienne B Shannon *Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Adrienne.shannon@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-7812-9627
Richard J Straker *Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Michael J CarrDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
James SunDepartment of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Karenia LandaDivision of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Kirsten BaecherDivision of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Kevin LynchDivision of Breast and Melanoma Surgery, Department of Surgery, University of Virginia, Charlottesville, VA, USA.
Harrison G BartelsDivision of Head and Neck Surgical Oncology, Department of Otolaryngology, University of Virginia, Charlottesville, VA, USA.
Robyn PanchaudDepartment of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Luke J KeeleDivision of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Michael C LoweDivision of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Craig L SlingluffDivision of Breast and Melanoma Surgery, Department of Surgery, University of Virginia, Charlottesville, VA, USA.
Mark J JamesonDivision of Head and Neck Surgical Oncology, Department of Otolaryngology, University of Virginia, Charlottesville, VA, USA.
Kenneth Y TsaiDepartment of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Mark B FariesDivision of Surgical Oncology, Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
Georgia M BeasleyDivision of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Vernon K SondakDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Giorgos C KarakousisDivision of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
John T MiuraDivision of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Hospital of the University of Pennsylvania · USUniversity of South Florida · USUniversity of Virginia · USDuke Medical Center · USEmory University · USCedars-Sinai Medical Center · USUniversity Hospitals of Cleveland · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMerkel cell carcinoma (MCC) is a rare cutaneous malignancy for which factors predictive of disease-specific survival (DSS) are poorly defined.

methodsPatients from six centers (2005-2020) with clinical stage I-II MCC who underwent sentinel lymph node (SLN) biopsy were included. Factors associated with DSS were identified using competing-risks regression analysis. Risk-score modeling was established using competing-risks regression on a training dataset and internally validated by point assignment to variables.

resultsOf 604 patients, 474 (78.5%) and 128 (21.2%) patients had clinical stage I and II disease, respectively, and 189 (31.3%) had SLN metastases. The 5-year DSS rate was 81.8% with a median follow-up of 31 months. Prognostic factors associated with worse DSS included increasing age (hazard ratio [HR] 1.03, p = 0.046), male sex (HR 3.21, p = 0.021), immune compromise (HR 2.46, p = 0.013), presence of microsatellites (HR 2.65, p = 0.041), and regional nodal involvement (1 node: HR 2.48, p = 0.039; ≥2 nodes: HR 2.95, p = 0.026). An internally validated, risk-score model incorporating all of these factors was developed with good performance (AUC 0.738). Patients with ≤ 4.00 and > 4.00 points had 5-year DSS rates of 89.4% and 67.2%, respectively. Five-year DSS for pathologic stage I/II patients with > 4.00 points (n = 49) was 79.8% and for pathologic stage III patients with ≤ 4.00 points (n = 62) was 90.3%.

conclusionsA risk-score model, including patient and tumor factors, based on DSS improves prognostic assessment of patients with clinically localized MCC. This may inform surveillance strategies and patient selection for adjuvant therapy trials.

Indexed as

Carcinoma, Merkel CellSkin NeoplasmsHumansLymphatic MetastasisMalePrognosisSentinel Lymph Node Biopsy

Identifiers

PMID35867209
OpenAlexW4286561371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.